Lars Wallentin

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Devices

Electrocardiography

Chemicals & Drugs

Concepts & Ideas

Procedures

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Lind Lars; Wallentin Lars; Kempf Tibor; Tapken Heike; Quint Anja; Lindahl Bertil; Olofsson Sylvia; Venge Per; Larsson Anders; Hulthe Johannes; Elmgren Anders; Wollert Kai C
Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study.
James Stefan K; Wallentin Lars; Lagerqvist Bo;
The SCAAR-scare in perspective.
Bonaca Marc P; Steg Philippe Gabriel; Feldman Laurent J; Canales John F; Ferguson James J; Wallentin Lars; Califf Robert M; Harrington Robert A; Giugliano Robert P
Antithrombotics in acute coronary syndromes.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Lars Wallentin (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Lind Lars; Wallentin Lars; Kempf Tibor; Tapken Heike; Quint Anja; Lindahl Bertil; Olofsson Sylvia; Venge Per; Larsson Anders; Hulthe Johannes; Elmgren Anders; Wollert Kai C
Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the Prospective Investigation of the Vasculature in Uppsala Seniors (PIVUS) Study.
European heart journal 2009;30(19):2346-53.
2009: James Stefan K; Wallentin Lars; Lagerqvist Bo;
The SCAAR-scare in perspective.
EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 2009;5(4):501-4.
2009: Bonaca Marc P; Steg Philippe Gabriel; Feldman Laurent J; Canales John F; Ferguson James J; Wallentin Lars; Califf Robert M; Harrington Robert A; Giugliano Robert P
Antithrombotics in acute coronary syndromes.
Journal of the American College of Cardiology 2009;54(11):969-84.
2009: Wallentin Lars; Becker Richard C; Budaj Andrzej; Cannon Christopher P; Emanuelsson Håkan; Held Claes; Horrow Jay; Husted Steen; James Stefan; Katus Hugo; Mahaffey Kenneth W; Scirica Benjamin M; Skene Allan; Steg Philippe Gabriel; Storey Robert F; Harrington Robert A; Freij Anneli; Thorsén Mona
Ticagrelor versus clopidogrel in patients with acute coronary syndromes.
The New England journal of medicine 2009;361(11):1045-57.
2009: Connolly Stuart J; Ezekowitz Michael D; Yusuf Salim; Eikelboom John; Oldgren Jonas; Parekh Amit; Pogue Janice; Reilly Paul A; Themeles Ellison; Varrone Jeanne; Wang Susan; Alings Marco; Xavier Denis; Zhu Jun; Diaz Rafael; Lewis Basil S; Darius Harald; Diener Hans-Christoph; Joyner Campbell D; Wallentin Lars;
Dabigatran versus warfarin in patients with atrial fibrillation.
The New England journal of medicine 2009;361(12):1139-51.
2009: Wallentin Lars
P2Y(12) inhibitors: differences in properties and mechanisms of action and potential consequences for clinical use.
European heart journal 2009;30(16):1964-77.
2009: Eggers Kai M; Lagerqvist Bo; Venge Per; Wallentin Lars; Lindahl Bertil
Prognostic value of biomarkers during and after non-ST-segment elevation acute coronary syndrome.
Journal of the American College of Cardiology 2009;54(4):357-64.
2009: Varenhorst Christoph; James Stefan; Erlinge David; Brandt John T; Braun Oscar O; Man Michael; Siegbahn Agneta; Walker Joseph; Wallentin Lars; Winters Kenneth J; Close Sandra L
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease.
European heart journal 2009;30(14):1744-52.
2009: Björck L; Rosengren A; Wallentin L; Stenestrand U
Smoking in relation to ST-segment elevation acute myocardial infarction: findings from the Register of Information and Knowledge about Swedish Heart Intensive Care Admissions.
Heart (British Cardiac Society) 2009;95(12):1006-11.
2009: Charytan David M; Wallentin Lars; Lagerqvist Bo; Spacek Rudolf; De Winter Robbert J; Stern Noam M; Braunwald Eugene; Cannon Christopher P; Choudhry Niteesh K
Early angiography in patients with chronic kidney disease: a collaborative systematic review.
Clinical journal of the American Society of Nephrology : CJASN 2009;4(6):1032-43.
2009: James Stefan K; Stenestrand Ulf; Lindbäck Johan; Carlsson Jörg; Scherstén Fredrik; Nilsson Tage; Wallentin Lars; Lagerqvist Bo;
Long-term safety and efficacy of drug-eluting versus bare-metal stents in Sweden.
The New England journal of medicine 2009;360(19):1933-45.
2009: Ezekowitz Michael D; Connolly Stuart; Parekh Amit; Reilly Paul A; Varrone Jeanne; Wang Susan; Oldgren Jonas; Themeles Ellison; Wallentin Lars; Yusuf Salim
Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran.
American heart journal 2009;157(5):805-10, 810.e1-2.
2009: Varenhorst Christoph; James Stefan; Erlinge David; Braun Oscar O; Brandt John T; Winters Kenneth J; Jakubowski Joseph A; Olofsson Sylvia; Wallentin Lars; Siegbahn Agneta
Assessment of P2Y(12) inhibition with the point-of-care device VerifyNow P2Y12 in patients treated with prasugrel or clopidogrel coadministered with aspirin.
American heart journal 2009;157(3):562.e1-9.
2009: Johanson Per; Fu Yuling; Wagner Galen S; Goodman Shaun G; Granger Chris B; Wallentin Lars; Van de Werf Frans; Armstrong Paul W;
ST resolution 1 hour after fibrinolysis for prediction of myocardial infarct size: insights from ASSENT 3.
The American journal of cardiology 2009;103(2):154-8.
2008: Erlinge David; Varenhorst Christoph; Braun Oscar O; James Stefan; Winters Kenneth J; Jakubowski Joseph A; Brandt John T; Sugidachi Atsuhiro; Siegbahn Agneta; Wallentin Lars
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
Journal of the American College of Cardiology 2008;52(24):1968-77.
2008: Ernest C Steven; Small David S; Rohatagi Shashank; Salazar Daniel E; Wallentin Lars; Winters Kenneth J; Wrishko Rebecca E
Population pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel in aspirin-treated patients with stable coronary artery disease.
Journal of pharmacokinetics and pharmacodynamics 2008;35(6):593-618.
2008: Norhammar A; Stenestrand U; Lindbäck J; Wallentin L;
Women younger than 65 years with diabetes mellitus are a high-risk group after myocardial infarction: a report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission (RIKS-HIA).
Heart (British Cardiac Society) 2008;94(12):1565-70.
2008: Braun Oscar O; Johnell Matilda; Varenhorst Christoph; James Stefan; Brandt John T; Jakubowski Joseph A; Winters Kenneth J; Wallentin Lars; Erlinge David; Siegbahn Agneta
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease.
Thrombosis and haemostasis 2008;100(4):626-33.
2008: Eggers Kai M; Kempf Tibor; Allhoff Tim; Lindahl Bertil; Wallentin Lars; Wollert Kai C
Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain.
European heart journal 2008;29(19):2327-35.
2008: Bassand Jean-Pierre; Hamm Christian W; Ardissino Diego; Boersma Eric; Budaj Andrzej; Fernandez-Aviles Francisco; Fox Keith A A; Hasdai David; Ohman E Magnus; Wallentin Lars; Wijns William;
[Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes]
Revista portuguesa de cardiologia : orgão oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology 2008;27(9):1063-143.
2008: Själander Anders; Wallentin Lars; Rosenqvist Mårten; Svensson Peter
[Antithrombotic treatment in atrial fibrillation. Background to new recommendations and therapeutic alternative]
Läkartidningen 2008;105(37):2478-80.
2008: Eggers Kai M; Lagerqvist Bo; Oldgren Jonas; Venge Per; Wallentin Lars; Lindahl Bertil
Pathophysiologic mechanisms of persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome.
American heart journal 2008;156(3):588-94.
2008: O'Donoghue Michelle; Boden William E; Braunwald Eugene; Cannon Christopher P; Clayton Tim C; de Winter Robbert J; Fox Keith A A; Lagerqvist Bo; McCullough Peter A; Murphy Sabina A; Spacek Rudolf; Swahn Eva; Wallentin Lars; Windhausen Fons; Sabatine Marc S
Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis.
JAMA : the journal of the American Medical Association 2008;300(1):71-80.
2008: Lopes R D; Pieper K S; Horton J R; Al-Khatib S M; Newby L K; Mehta R H; Van de Werf F; Armstrong P W; Mahaffey K W; Harrington R A; Ohman E M; White H D; Wallentin L; Granger C B
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation.
Heart (British Cardiac Society) 2008;94(7):867-73.
2008: Mälarstig A; Eriksson P; Hamsten A; Lindahl B; Wallentin L; Siegbahn A
Raised interleukin-10 is an indicator of poor outcome and enhanced systemic inflammation in patients with acute coronary syndrome.
Heart (British Cardiac Society) 2008;94(6):724-9.
2008: Eklund Kristina; Grip Lars; Israelsson Bo; Levin Lars-Ake; Lindahl Bertil; Wallentin Lars
[2008 National Cardiology Guidelines: Prioritization requires consideration to other factors than scientific studies alone]
Läkartidningen 2008;105(19):1408-9; discussion 1409.
2008: Jackson Kevin; Gersh Bernard J; Stockbridge Norman; Fleming Thomas R; Temple Robert; Califf Robert M; Connolly Stuart J; Wallentin Lars; Granger Christopher B;
Antithrombotic drug development for atrial fibrillation: proceedings, Washington, DC, July 25-27, 2005.
American heart journal 2008;155(5):829-40.
2008: Mälarstig Anders; Sigurdsson Snaevar; Eriksson Per; Paulsson-Berne Gabrielle; Hedin Ulf; Wallentin Lars; Siegbahn Agneta; Hamsten Anders; Syvänen Ann-Christine
Variants of the interferon regulatory factor 5 gene regulate expression of IRF5 mRNA in atherosclerotic tissue but are not associated with myocardial infarction.
Arteriosclerosis, thrombosis, and vascular biology 2008;28(5):975-82.
2008: Wallentin Lars; Lindahl Bertil; Kärvinge Christina; Eklund Kristina; Levin Lars-Ake; Grip Lars
[Swedish work with national guidelines can become an international model. With perspectives from cardiovascular diseases guidelines]
Läkartidningen 2008;105(16):1194-7.
2008: Toma M; Fu Y; Wagner G; Goodman S G; Granger C; Wallentin L; Van de Werf F; Armstrong P
Risk stratification in ST-elevation myocardial infarction is enhanced by combining baseline ST deviation and subsequent ST-segment resolution.
Heart (British Cardiac Society) 2008;94(3):e6.
2008: Peters Ron J G; Joyner Campbell; Bassand Jean-Pierre; Afzal Rizwan; Chrolavicius Susan; Mehta Shamir R; Oldgren Jonas; Wallentin Lars; Budaj Andrzej; Fox Keith A; Yusuf Salim;
The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial.
European heart journal 2008;29(3):324-31.
2008: Oldgren Jonas; Wallentin Lars; Afzal Rizwan; Bassand Jean-Pierre; Budaj Andrzej; Chrolavicius Susan; Fox Keith A A; Granger Christopher B; Mehta Shamir R; Pais Prem; Peters Ron J G; Xavier Denis; Zhu Jun; Yusuf Salim;
Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment.
European heart journal 2008;29(3):315-23.
2008: Wallentin Lars; Varenhorst Christoph; James Stefan; Erlinge David; Braun Oscar O; Jakubowski Joseph A; Sugidachi Atsuhiro; Winters Kenneth J; Siegbahn Agneta
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease.
European heart journal 2008;29(1):21-30.
2007: Kempf Tibor; Björklund Erik; Olofsson Sylvia; Lindahl Bertil; Allhoff Tim; Peter Timo; Tongers Jörn; Wollert Kai C; Wallentin Lars
Growth-differentiation factor-15 improves risk stratification in ST-segment elevation myocardial infarction.
European heart journal 2007;28(23):2858-65.
2007: Norhammar Anna; Lindbäck Johan; Rydén Lars; Wallentin Lars; Stenestrand Ulf;
Improved but still high short- and long-term mortality rates after myocardial infarction in patients with diabetes mellitus: a time-trend report from the Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admission.
Heart (British Cardiac Society) 2007;93(12):1577-83.
2007: Ezekowitz Michael D; Reilly Paul A; Nehmiz Gerhard; Simmers Timothy A; Nagarakanti Rangadham; Parcham-Azad Kambiz; Pedersen K Erik; Lionetti Dominick A; Stangier Joachim; Wallentin Lars
Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study).
The American journal of cardiology 2007;100(9):1419-26.
2007: Mark Daniel B; Van de Werf Frans J; Simes R John; White Harvey D; Wallentin Lars C; Califf Robert M; Armstrong Paul W;
Cardiovascular disease on a global scale: defining the path forward for research and practice.
European heart journal 2007;28(21):2678-84.
2007: Alfredsson Joakim; Stenestrand Ulf; Wallentin Lars; Swahn Eva
Gender differences in management and outcome in non-ST-elevation acute coronary syndrome.
Heart (British Cardiac Society) 2007;93(11):1357-62.
2007: Mehta Shamir R; Granger Christopher B; Eikelboom John W; Bassand Jean-Pierre; Wallentin Lars; Faxon David P; Peters Ron J G; Budaj Andrzej; Afzal Rizwan; Chrolavicius Susan; Fox Keith A A; Yusuf Salim
Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial.
Journal of the American College of Cardiology 2007;50(18):1742-51.
2007: Eggers Kai M; Lagerqvist Bo; Venge Per; Wallentin Lars; Lindahl Bertil
Persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome predicts long-term mortality.
Circulation 2007;116(17):1907-14.
2007: Wollert Kai C; Kempf Tibor; Lagerqvist Bo; Lindahl Bertil; Olofsson Sylvia; Allhoff Tim; Peter Timo; Siegbahn Agneta; Venge Per; Drexler Helmut; Wallentin Lars
Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome.
Circulation 2007;116(14):1540-8.
2007: Tabrizi Fariborz; Englund Anders; Rosenqvist Mårten; Wallentin Lars; Stenestrand Ulf
Influence of left bundle branch block on long-term mortality in a population with heart failure.
European heart journal 2007;28(20):2449-55.
2007: Fox Keith A A; Bassand Jean-Pierre; Mehta Shamir R; Wallentin Lars; Theroux Pierre; Piegas Leopoldo Soares; Valentin Vicent; Moccetti Tiziano; Chrolavicius Susan; Afzal Rizwan; Yusuf Salim;
Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes.
Annals of internal medicine 2007;147(5):304-10.
2007: Westerhout Cynthia M; Lauer Michael S; James Stefan; Fu Yuling; Wallentin Lars; Armstrong Paul W;
Electrocardiographic left ventricular hypertrophy in GUSTO IV ACS: an important risk marker of mortality in women.
European heart journal 2007;28(17):2064-9.
2007: Westerhout Cynthia M; Gnarpe Judy; Chang Wei-Ching; FitzPatrick Susan; Barnathan Elliot S; Boersma Eric; Califf Robert M; Wallentin Lars; Simoons Maarten L; Armstrong Paul W;
No prognostic significance of chronic infection with Chlamydia pneumoniae in acute coronary syndromes: insights from the Global Utilization of Strategies to Open Occluded Arteries IV Acute Coronary Syndromes trial.
American heart journal 2007;154(2):306-12.
2007: Bassand Jean-Pierre; Hamm Christian W; Ardissino Diego; Boersma Eric; Budaj Andrzej; Fernández-Avilés Francisco; Fox Keith A A; Hasdai David; Ohman E Magnus; Wallentin Lars; Wijns William
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes.
European heart journal 2007;28(13):1598-660.
2007: Stenestrand Ulf; Lindahl Bertil; Wallentin Lars
[Care of myocardial infarction strongly improved 1995-2005. Quality registry, open statements and clear therapeutic goals have payed off]
Läkartidningen 2007;104(20-21):1580-3.
2007: De Caterina Raffaele; Husted Steen; Wallentin Lars; Agnelli Giancarlo; Bachmann Fedor; Baigent Colin; Jespersen Jørgen; Kristensen Steen Dalby; Montalescot Gilles; Siegbahn Agneta; Verheugt Freek W A; Weitz Jeffrey
Anticoagulants in heart disease: current status and perspectives.
European heart journal 2007;28(7):880-913.
2007: Hernández Adrián V; Westerhout Cynthia M; Steyerberg Ewout W; Ioannidis John P A; Bueno Héctor; White Harvey; Theroux Pierre; Moliterno David J; Armstrong Paul W; Califf Robert M; Wallentin Lars C; Simoons Maarten L; Boersma Eric
Effects of platelet glycoprotein IIb/IIIa receptor blockers in non-ST segment elevation acute coronary syndromes: benefit and harm in different age subgroups.
Heart (British Cardiac Society) 2007;93(4):450-5.
2007: Christersson Christina; Oldgren Jonas; Bylock Anders; Siegbahn Agneta; Wallentin Lars
Early decrease in coagulation activity after myocardial infarction is associated with lower risk of new ischaemic events: observations from the ESTEEM Trial.
European heart journal 2007;28(6):692-8.
2007: Oldgren Jonas; James Stefan K; Siegbahn Agneta; Wallentin Lars
Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients.
European heart journal 2007;28(6):699-704.
2007: Lagerqvist Bo; James Stefan K; Stenestrand Ulf; Lindbäck Johan; Nilsson Tage; Wallentin Lars;
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden.
The New England journal of medicine 2007;356(10):1009-19.
2007: Bugiardini Raffaele; Badimon Lina; Collins Peter; Erbel Raimund; Fox Kim; Hamm Christian; Pinto Fausto; Rosengren Annika; Stefanadis Christodoulos; Wallentin Lars; Van de Werf Frans
Angina, "normal" coronary angiography, and vascular dysfunction: risk assessment strategies.
PLoS medicine 2007;4(2):e12.
2007: Wollert Kai C; Kempf Tibor; Peter Timo; Olofsson Sylvia; James Stefan; Johnston Nina; Lindahl Bertil; Horn-Wichmann Rüdiger; Brabant Georg; Simoons Maarten L; Armstrong Paul W; Califf Robert M; Drexler Helmut; Wallentin Lars
Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome.
Circulation 2007;115(8):962-71.
2007: Kempf Tibor; Horn-Wichmann Rüdiger; Brabant Georg; Peter Timo; Allhoff Tim; Klein Gunnar; Drexler Helmut; Johnston Nina; Wallentin Lars; Wollert Kai C
Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay.
Clinical chemistry 2007;53(2):284-91.
2007: Jakubowski Joseph A; Winters Kenneth J; Naganuma Hideo; Wallentin Lars
Prasugrel: a novel thienopyridine antiplatelet agent. A review of preclinical and clinical studies and the mechanistic basis for its distinct antiplatelet profile.
Cardiovascular drug reviews 2007;25(4):357-74.
2007: Mälarstig Anders; Wallentin Lars; Siegbahn Agneta
Genetic variation in the interleukin-6 gene in relation to risk and outcomes in acute coronary syndrome.
Thrombosis research 2007;119(4):467-73.
2006: Carlhed Rickard; Bojestig Mats; Wallentin Lars; Lindström Gunilla; Peterson Anette; Aberg Christina; Lindahl Bertil;
Improved adherence to Swedish national guidelines for acute myocardial infarction: the Quality Improvement in Coronary Care (QUICC) study.
American heart journal 2006;152(6):1175-81.
2006: Johnston Nina; Jernberg Tomas; Lagerqvist Bo; Wallentin Lars
Early invasive treatment benefits patients with renal dysfunction in unstable coronary artery disease.
American heart journal 2006;152(6):1052-8.
2006: Westerhout Cynthia M; Hernández Adrián V; Steyerberg Ewout W; Bueno Héctor; White Harvey; Théroux Pierre; Moliterno David J; Armstrong Paul W; Califf Robert M; Wallentin Lars C; Simoons Maarten L; Boersma Eric
Predictors of stroke within 30 days in patients with non-ST-segment elevation acute coronary syndromes.
European heart journal 2006;27(24):2956-61.
2006: Johnston Nina; Jernberg Tomas; Lagerqvist Bo; Siegbahn Agneta; Wallentin Lars
Oxidized low-density lipoprotein as a predictor of outcome in patients with unstable coronary artery disease.
International journal of cardiology 2006;113(2):167-73.
2006: Stenestrand Ulf; Lindbäck Johan; Wallentin Lars;
Long-term outcome of primary percutaneous coronary intervention vs prehospital and in-hospital thrombolysis for patients with ST-elevation myocardial infarction.
JAMA : the journal of the American Medical Association 2006;296(14):1749-56.
2006: Sinnaeve Peter R; Huang Yao; Bogaerts Kris; Vahanian Alec; Adgey Jennifer; Armstrong Paul W; Wallentin Lars; Van de Werf Frans J; Granger Christopher B;
Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS.
American heart journal 2006;152(4):684.e1-9.
2006: Mandelzweig Lori; Battler Alex; Boyko Valentina; Bueno Hector; Danchin Nicolas; Filippatos Gerasimos; Gitt Anselm; Hasdai David; Hasin Yonathan; Marrugat Jaume; Van de Werf Frans; Wallentin Lars; Behar Shlomo;
The second Euro Heart Survey on acute coronary syndromes: Characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004.
European heart journal 2006;27(19):2285-93.
2006: Lagerqvist Bo; Husted Steen; Kontny Fredrik; Ståhle Elisabeth; Swahn Eva; Wallentin Lars;
5-year outcomes in the FRISC-II randomised trial of an invasive versus a non-invasive strategy in non-ST-elevation acute coronary syndrome: a follow-up study.
Lancet 2006;368(9540):998-1004.
2006: James Stefan K; Lindbäck Johan; Tilly Johanna; Siegbahn Agneta; Venge Per; Armstrong Paul; Califf Robert; Simoons Maarten L; Wallentin Lars; Lindahl Bertil
Troponin-T and N-terminal pro-B-type natriuretic peptide predict mortality benefit from coronary revascularization in acute coronary syndromes: a GUSTO-IV substudy.
Journal of the American College of Cardiology 2006;48(6):1146-54.
2006: Westerhout Cynthia M; Fu Yuling; Lauer Michael S; James Stefan; Armstrong Paul W; Al-Hattab Eyad; Califf Robert M; Simoons Maarten L; Wallentin Lars; Boersma Eric;
Short- and long-term risk stratification in acute coronary syndromes: the added value of quantitative ST-segment depression and multiple biomarkers.
Journal of the American College of Cardiology 2006;48(5):939-47.
2006: Lenderink Timo; Boersma Eric; Gitt Anselm K; Zeymer Uwe; Wallentin Lars; Van de Werf Frans; Hasdai David; Behar Shlomo; Simoons Maarten L
Patients using statin treatment within 24 h after admission for ST-elevation acute coronary syndromes had lower mortality than non-users: a report from the first Euro Heart Survey on acute coronary syndromes.
European heart journal 2006;27(15):1799-804.
2006: Mälarstig Anders; Lindahl Bertil; Wallentin Lars; Siegbahn Agneta
Soluble CD40L levels are regulated by the -3459 A>G polymorphism and predict myocardial infarction and the efficacy of antithrombotic treatment in non-ST elevation acute coronary syndrome.
Arteriosclerosis, thrombosis, and vascular biology 2006;26(7):1667-73.
2006: Björklund E; Jernberg T; Johanson P; Venge P; Dellborg M; Wallentin L; Lindahl B;
Admission N-terminal pro-brain natriuretic peptide and its interaction with admission troponin T and ST segment resolution for early risk stratification in ST elevation myocardial infarction.
Heart (British Cardiac Society) 2006;92(6):735-40.
2006: Armstrong Paul W; Chang Wei-Ching; Wallentin Lars; Goldstein Patrick; Granger Christopher B; Bogaerts Kris; Danays Thierry; Van de Werf Frans;
Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 2006;174(10):1421-6.
2006: Björklund Erik; Stenestrand Ulf; Lindbäck Johan; Svensson Leif; Wallentin Lars; Lindahl Bertil
Pre-hospital thrombolysis delivered by paramedics is associated with reduced time delay and mortality in ambulance-transported real-life patients with ST-elevation myocardial infarction.
European heart journal 2006;27(10):1146-52.
2006: Jernberg Tomas; Payne Christopher D; Winters Kenneth J; Darstein Christelle; Brandt John T; Jakubowski Joseph A; Naganuma Hideo; Siegbahn Agneta; Wallentin Lars
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
European heart journal 2006;27(10):1166-73.
2006: Yusuf Salim; Mehta Shamir R; Chrolavicius Susan; Afzal Rizwan; Pogue Janice; Granger Christopher B; Budaj Andrzej; Peters Ron J G; Bassand Jean-Pierre; Wallentin Lars; Joyner Campbell; Fox Keith A A;
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial.
JAMA : the journal of the American Medical Association 2006;295(13):1519-30.
2006: Yusuf Salim; Mehta Shamir R; Chrolavicius Susan; Afzal Rizwan; Pogue Janice; Granger Christopher B; Budaj Andrzej; Peters Ron J G; Bassand Jean-Pierre; Wallentin Lars; Joyner Campbell; Fox Keith A A
Comparison of fondaparinux and enoxaparin in acute coronary syndromes.
The New England journal of medicine 2006;354(14):1464-76.
2006: Rosengren Annika; Wallentin Lars; Simoons Maarten; Gitt Anselm K; Behar Solomon; Battler Alexander; Hasdai David
Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey.
European heart journal 2006;27(7):789-95.
2006: Johnston Nina; Jernberg Tomas; Lagerqvist Bo; Siegbahn Agneta; Wallentin Lars
Improved identification of patients with coronary artery disease by the use of new lipid and lipoprotein biomarkers.
The American journal of cardiology 2006;97(5):640-5.
2006: Chang Wei-Ching; Kaul Padma; Fu Yuling; Westerhout Cynthia M; Granger Christopher B; Mahaffey Kenneth W; Wallentin Lars; Van de Werf Frans; Armstrong Paul W;
Forecasting mortality: dynamic assessment of risk in ST-segment elevation acute myocardial infarction.
European heart journal 2006;27(4):419-26.
2006: James Stefan K; Lindahl Bertil; Timmer Jorik R; Ottervanger Jan Paul; Siegbahn Agneta; Stridsberg Mats; Armstrong Paul; Califf Robert; Wallentin Lars; Simoons Maarten L
Usefulness of biomarkers for predicting long-term mortality in patients with diabetes mellitus and non-ST-elevation acute coronary syndromes (a GUSTO IV substudy).
The American journal of cardiology 2006;97(2):167-72.
2006: Al-Faleh Hussam; Fu Yuling; Wagner Galen; Goodman Shaun; Sgarbossa Elena; Granger Christopher; Van de Werf Frans; Wallentin Lars; Armstrong Paul W;
Unraveling the spectrum of left bundle branch block in acute myocardial infarction: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials.
American heart journal 2006;151(1):10-5.
2005: Mehta Shamir R; Yusuf Salim; Granger Christopher B; Wallentin Lars; Peters Ron J G; Bassand Jean-Pierre; Budaj Andrzej; Joyner Campbell; Chrolavicius Susan; Fox Keith A A
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes.
American heart journal 2005;150(6):1107.
2005: Mälarstig Anders; Tenno Taavo; Johnston Nina; Lagerqvist Bo; Axelsson Tomas; Syvänen Ann-Christine; Wallentin Lars; Siegbahn Agneta
Genetic variations in the tissue factor gene are associated with clinical outcome in acute coronary syndrome and expression levels in human monocytes.
Arteriosclerosis, thrombosis, and vascular biology 2005;25(12):2667-72.
2005: Stenestrand Ulf; Lindbäck Johan; Wallentin Lars;
Anticoagulation therapy in atrial fibrillation in combination with acute myocardial infarction influences long-term outcome: a prospective cohort study from the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA).
Circulation 2005;112(21):3225-31.
2005: Oldgren J; Fellenius C; Boman K; Jansson J-H; Nilsson T K; Wallentin L; Siegbahn A
Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease.
Journal of internal medicine 2005;258(5):420-7.
2005: Welsh R C; Chang W; Goldstein P; Adgey J; Granger C B; Verheugt F W A; Wallentin L; Van de Werf F; Armstrong P W;
Time to treatment and the impact of a physician on prehospital management of acute ST elevation myocardial infarction: insights from the ASSENT-3 PLUS trial.
Heart (British Cardiac Society) 2005;91(11):1400-6.
2005: Björklund Erik; Stenestrand Ulf; Lindbäck Johan; Svensson Leif; Wallentin Lars; Lindahl Bertil;
Prehospital diagnosis and start of treatment reduces time delay and mortality in real-life patients with STEMI.
Journal of electrocardiology 2005;38(4 Suppl):186.
2005: Christersson C; Oldgren J; Bylock A; Wallentin L; Siegbahn A
Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction.
Journal of thrombosis and haemostasis : JTH 2005;3(10):2245-53.
2005: Rosengren A; Wallentin L; Simoons M; Gitt A K; Behar S; Battler A; Hasdai D
Cardiovascular risk factors and clinical presentation in acute coronary syndromes.
Heart (British Cardiac Society) 2005;91(9):1141-7.
2005: Johanson Per; Fu Yuling; Goodman Shaun G; Dellborg Mikael; Armstrong Paul W; Krucoff Mitchell W; Wallentin Lars; Wagner Galen S
A dynamic model forecasting myocardial infarct size before, during, and after reperfusion therapy: an ASSENT-2 ECG/VCG substudy.
European heart journal 2005;26(17):1726-33.
2005: Wallentin Lars
Prevention of cardiovascular events after acute coronary syndrome.
Seminars in vascular medicine 2005;5(3):293-300.
2005: Lagerqvist B; Diderholm E; Lindahl B; Husted S; Kontny F; Ståhle E; Swahn E; Venge P; Siegbahn A; Wallentin L
FRISC score for selection of patients for an early invasive treatment strategy in unstable coronary artery disease.
Heart (British Cardiac Society) 2005;91(8):1047-52.
2005: Hasin Yonathan; Danchin Nicolas; Filippatos Gerasimos S; Heras Magda; Janssens Uwe; Leor Jonathan; Nahir Menachem; Parkhomenko Alexander; Thygesen Kristian; Tubaro Marco; Wallentin Lars C; Zakke Ilia;
Recommendations for the structure, organization, and operation of intensive cardiac care units.
European heart journal 2005;26(16):1676-82.
2005: Ripa Rasmus S; Holmvang Lene; Maynard Charles; Sejersten Maria; Clemmensen Peter; Grande Peer; Lindahl Bertil; Lagerqvist Bo; Wallentin Lars; Wagner Galen S
Consideration of the total ST-segment deviation on the initial electrocardiogram for predicting final acute posterior myocardial infarct size in patients with maximum ST-segment deviation as depression in leads V1 through V3. A FRISC II substudy.
Journal of electrocardiology 2005;38(3):180-6.
2005: Mehta Shamir R; Cannon Christopher P; Fox Keith A A; Wallentin Lars; Boden William E; Spacek Rudolf; Widimsky Petr; McCullough Peter A; Hunt David; Braunwald Eugene; Yusuf Salim
Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials.
JAMA : the journal of the American Medical Association 2005;293(23):2908-17.
2005: Jernberg Tomas; James Stefan; Lindahl Bertil; Stridsberg Mats; Venge Per; Wallentin Lars
NT-ProBNP in non-ST-elevation acute coronary syndrome.
Journal of cardiac failure 2005;11(5 Suppl):S54-8.
2005: Chang Wei-Ching; Midodzi William K; Westerhout Cynthia M; Boersma Eric; Cooper Judith; Barnathan Elliot S; Simoons Maarten L; Wallentin Lars; Ohman E Magnus; Armstrong Paul W
Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis.
Journal of epidemiology and community health 2005;59(5):427-33.
2005: Wallentin Lars
Treatment of acute coronary syndromes: have we reached the ceiling?
Nature clinical practice. Cardiovascular medicine 2005;2(4):173.
2005: James Stefan K; Oldgren Jonas; Lindbäck Johan; Johnston Nina; Siegbahn Agneta; Wallentin Lars
An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease.
American heart journal 2005;149(4):619-26.
2005: Wallentin Lars
[Insights and views about cardiovascular safety of COX2 inhibitors]
Läkartidningen 2005;102(9):666, 668, 671.
2005: Lindahl Bertil; Lindbäck Johan; Jernberg Tomas; Johnston Nina; Stridsberg Mats; Venge Per; Wallentin Lars
Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy.
Journal of the American College of Cardiology 2005;45(4):533-41.
2005: Flynn M Rachel; Barrett Conor; Cosío Francisco G; Gitt Anselm K; Wallentin Lars; Kearney Peter; Lonergan Moira; Shelley Emer; Simoons Maarten L
The Cardiology Audit and Registration Data Standards (CARDS), European data standards for clinical cardiology practice.
European heart journal 2005;26(3):308-13.
2005: Frostfeldt Gunnar; Sörensen Jens; Lindahl Bertil; Valind Sven; Wallentin Lars
Development of myocardial microcirculation and metabolism in acute ST-elevation myocardial infarction evaluated with positron emission tomography.
Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 2005;12(1):43-54.
2005: Stenestrand Ulf; Lindbäck Johan; Wallentin Lars
Hospital therapy traditions influence long-term survival in patients with acute myocardial infarction.
American heart journal 2005;149(1):82-90.
2005: Jacobsen Michael D; Wagner Galen S; Holmvang Lene; Kontny Frederic; Wallentin Lars; Husted Steen; Swahn Eva; Ståhle Elisabeth; Steffensen Rolf; Clemmensen Peter
Quantitative T-wave analysis predicts 1 year prognosis and benefit from early invasive treatment in the FRISC II study population.
European heart journal 2005;26(2):112-8.
2004: Jernberg Tomas; Lindahl Bertil; James Stefan; Larsson Anders; Hansson Lars-Olof; Wallentin Lars
Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome.
Circulation 2004;110(16):2342-8.
2004: Patrono Carlo; Bachmann Fedor; Baigent Colin; Bode Christopher; De Caterina Raffaele; Charbonnier Bernard; Fitzgerald Desmond; Hirsh Jack; Husted Steen; Kvasnicka Jan; Montalescot Gilles; García Rodríguez Luis Alberto; Verheugt Freek; Vermylen Jozef; Wallentin Lars;
[Expert consensus document on the use of antiplatelet agents]
Revista española de cardiología 2004;57(10):963-80.
2004: Björklund Erik; Lindahl Bertil; Stenestrand Ulf; Swahn Eva; Dellborg Mikael; Pehrsson Kenneth; Van De Werf Frans; Wallentin Lars;
Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale clinical trial.
American heart journal 2004;148(4):566-73.
2004: Stenestrand Ulf; Tabrizi Fariborz; Lindbäck Johan; Englund Anders; Rosenqvist Mårten; Wallentin Lars
Comorbidity and myocardial dysfunction are the main explanations for the higher 1-year mortality in acute myocardial infarction with left bundle-branch block.
Circulation 2004;110(14):1896-902.
2004: Ottervanger J P; Armstrong P; Barnathan E S; Boersma E; Cooper J S; Ohman E M; James S; Wallentin L; Simoons M L;
Association of revascularisation with low mortality in non-ST elevation acute coronary syndrome, a report from GUSTO IV-ACS.
European heart journal 2004;25(17):1494-501.
2004: Jernberg Tomas; James Stefan; Lindahl Bertil; Johnston Nina; Stridsberg Mats; Venge Per; Wallentin Lars
Natriuretic peptides in unstable coronary artery disease.
European heart journal 2004;25(17):1486-93.
2004: Curtis Jeptha P; Alexander John H; Huang Yao; Wallentin Lars; Verheugt Freek W A; Armstrong Paul W; Krumholz Harlan M; Van de Werf Frans; Danays Thierry; Cheeks Morris; Granger Christopher B;
Efficacy and safety of two unfractionated heparin dosing strategies with tenecteplase in acute myocardial infarction (results from Assessment of the Safety and Efficacy of a New Thrombolytic Regimens 2 and 3).
The American journal of cardiology 2004;94(3):279-83.
2004: Taher Taha; Fu Yuling; Wagner Galen S; Goodman Shaun G; Fresco Claudio; Granger Christopher B; Wallentin Lars; van de Werf Frans; Verheugt Freek; Armstrong Paul W
Aborted myocardial infarction in patients with ST-segment elevation: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy.
Journal of the American College of Cardiology 2004;44(1):38-43.
2004: Sinnaeve Peter R; Alexander John H; Bogaerts Kris; Belmans Ann; Wallentin Lars; Armstrong Paul; Adgey Jennifer A A; Tendera Michal; Diaz Rafael; Soares-Piegas Leopoldo; Vahanian Alec; Granger Christopher B; Van De Werf Frans J
Efficacy of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: one-year follow-up results of the Assessment of the Safety of a New Thrombolytic-3 (ASSENT-3) randomized trial in acute myocardial infarction.
American heart journal 2004;147(6):993-8.
2004: Welsh Robert C; Goldstein Patrick; Adgey Jennifer; Verheugt Freek; Bestilny Shirley A; Wallentin Lars; Van de Werf Frans; Armstrong Paul W;
Variations in pre-hospital fibrinolysis process of care: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic 3 Plus international acute myocardial infarction pre-hospital care survey.
European journal of emergency medicine : official journal of the European Society for Emergency Medicine 2004;11(3):134-40.
2004: Lenderink Timo; Boersma Eric; Ruzyllo Witold; Widimsky Petr; Ohman E Magnus; Armstrong Paul W; Wallentin Lars; Simoons Maarten L;
Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
American heart journal 2004;147(5):865-73.
2004: Johanson Per; Wallentin Lars; Nilsson Tage; Bergstrand Lott; Lindahl Bertil; Dellborg Mikael
ST-segment analyses and residual thrombi in the infarct-related artery: a report from the ASSENT PLUS ST-monitoring substudy.
American heart journal 2004;147(5):853-8.
2004: Wu Alan H B; Packer Milton; Smith Andrew; Bijou Rachel; Fink Daniel; Mair Johannes; Wallentin Lars; Johnston Nina; Feldcamp Carolyn S; Haverstick Doris M; Ahnadi Charaf E; Grant Andrew; Despres Normand; Bluestein Barry; Ghani Farooq
Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure: a multisite study.
Clinical chemistry 2004;50(5):867-73.
2004: James Stefan; Lindahl Bertil; Siegbahn Agneta; Stridsberg Mats; Venge Per; Wallentin Lars
[Prognosis in unstable coronary artery disease. Multimarker strategy is the best basis for the therapeutic choice]
Läkartidningen 2004;101(17):1514-9, 1521-2.
2004: Rosengren Annika; Wallentin Lars; K Gitt Anselm; Behar Solomon; Battler Alexander; Hasdai David
Sex, age, and clinical presentation of acute coronary syndromes.
European heart journal 2004;25(8):663-70.
2004: Jernberg Tomas; James Stefan; Lindahl Bertil; Stridsberg Mats; Venge Per; Wallentin Lars
NT-proBNP in unstable coronary artery disease--experiences from the FAST, GUSTO IV and FRISC II trials.
European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology 2004;6(3):319-25.
2004: Johnston Nina; Jernberg Tomas; Lindahl Bertil; Lindbäck Johan; Stridsberg Mats; Larsson Anders; Venge Per; Wallentin Lars
Biochemical indicators of cardiac and renal function in a healthy elderly population.
Clinical biochemistry 2004;37(3):210-6.
2004: James Stefan K; Lindahl Bertil; Armstrong Paul; Califf Robert; Simoons M L Maarten L; Venge Per; Wallentin Lars;
A rapid troponin I assay is not optimal for determination of troponin status and prediction of subsequent cardiac events at suspicion of unstable coronary syndromes.
International journal of cardiology 2004;93(2-3):113-20.
2004: Norhammar Anna; Malmberg Klas; Diderholm Erik; Lagerqvist Bo; Lindahl Bertil; Rydén Lars; Wallentin Lars
Diabetes mellitus: the major risk factor in unstable coronary artery disease even after consideration of the extent of coronary artery disease and benefits of revascularization.
Journal of the American College of Cardiology 2004;43(4):585-91.
2004: Oldgren Jonas; Siegbahn Agneta; Grip Lars; Linder Rikard; Thygesen Kristian; Wallentin Lars
Myocardial damage, coagulation activity and the response to thrombin inhibition in unstable coronary artery disease.
Thrombosis and haemostasis 2004;91(2):381-7.
2004: James Stefan K; Siegbahn Agneta; Armstrong Paul; Barnathan Elliott; Califf Robert; Simoons Maarten L; Wallentin Lars
Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy.
American heart journal 2004;147(2):267-74.
2004: Björklund Erik; Lindahl Bertil; Johanson Per; Jernberg Tomas; Svensson Ann Marie; Venge Per; Wallentin Lars; Dellborg Mikael;
Admission Troponin T and measurement of ST-segment resolution at 60 min improve early risk stratification in ST-elevation myocardial infarction.
European heart journal 2004;25(2):113-20.
2003: Jernberg Tomas; Lindahl Bertil; Siegbahn Agneta; Andren Bertil; Frostfeldt Gunnar; Lagerqvist Bo; Stridsberg Mats; Venge Per; Wallentin Lars
N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease.
Journal of the American College of Cardiology 2003;42(11):1909-16.
2003: Diderholm Erik; Andrén Bertil; Frostfeldt Gunnar; Genberg Margareta; Jernberg Tomas; Lagerqvist Bo; Lindahl Bertil; Wallentin Lars
Effects of an early invasive strategy on ischemia and exercise tolerance among patients with unstable coronary artery disease.
The American journal of medicine 2003;115(8):606-12.
2003: Dubois Christophe L; Belmans Ann; Granger Christopher B; Armstrong Paul W; Wallentin Lars; Fioretti Paolo M; López-Sendón José L; Verheugt Freek W; Meyer Jürgen; Van de Werf Frans;
Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab.
Journal of the American College of Cardiology 2003;42(7):1178-85.
2003: Wallentin Lars; Wilcox Robert G; Weaver W Douglas; Emanuelsson Håkan; Goodvin Andrew; Nyström Per; Bylock Anders;
Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.
Lancet 2003;362(9386):789-97.
2003: James Stefan; Armstrong Paul; Califf Robert; Simoons Maarten L; Venge Per; Wallentin Lars; Lindahl Bertil
Troponin T levels and risk of 30-day outcomes in patients with the acute coronary syndrome: prospective verification in the GUSTO-IV trial.
The American journal of medicine 2003;115(3):178-84.
2003: Armstrong Paul W; Wagner Galen; Goodman Shaun G; Van de Werf Frans; Granger Christopher; Wallentin Lars; Fu Yuling;
ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction.
European heart journal 2003;24(16):1515-22.
2003: Wallentin L; Goldstein P; Armstrong P W; Granger C B; Adgey A A J; Arntz H R; Bogaerts K; Danays T; Lindahl B; Mäkijärvi M; Verheugt F; Van de Werf F
Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction.
Circulation 2003;108(2):135-42.
2003: James Stefan K; Lindahl Bertil; Siegbahn Agneta; Stridsberg Mats; Venge Per; Armstrong Paul; Barnathan Elliot S; Califf Robert; Topol Eric J; Simoons Maarten L; Wallentin Lars
N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy.
Circulation 2003;108(3):275-81.
2003: Venge Per; Johnston Nina; Lagerqvist Bo; Wallentin Lars; Lindahl Bertil;
Clinical and analytical performance of the liaison cardiac troponin I assay in unstable coronary artery disease, and the impact of age on the definition of reference limits. A FRISC-II substudy.
Clinical chemistry 2003;49(6 Pt 1):880-6.
2003: Norhammar Anna; Malmberg Klas; Rydén Lars; Tornvall Per; Stenestrand Ulf; Wallentin Lars;
Under utilisation of evidence-based treatment partially explains for the unfavourable prognosis in diabetic patients with acute myocardial infarction.
European heart journal 2003;24(9):838-44.
2003: Lidell Christer; Svedberg Lars-Erik; Lindell Peter; Bandh Stellan; Job Bernhard; Wallentin Lars
Clopidogrel and warfarin: absence of interaction in patients receiving long-term anticoagulant therapy for non-valvular atrial fibrillation.
Thrombosis and haemostasis 2003;89(5):842-6.
2003: Wallentin Lars; Bergstrand Lott; Dellborg Mikael; Fellenius Carin; Granger Christopher B; Lindahl Bertil; Lins Lars Eric; Nilsson Tage; Pehrsson Kenneth; Siegbahn Agneta; Swahn Eva
Low molecular weight heparin (dalteparin) compared to unfractionated heparin as an adjunct to rt-PA (alteplase) for improvement of coronary artery patency in acute myocardial infarction-the ASSENT Plus study.
European heart journal 2003;24(10):897-908.
2003: Stenestrand Ulf; Wallentin Lars;
Fibrinolytic therapy in patients 75 years and older with ST-segment-elevation myocardial infarction: one-year follow-up of a large prospective cohort.
Archives of internal medicine 2003;163(8):965-71.
2003: James Stefan K; Armstrong Paul; Barnathan Elliott; Califf Robert; Lindahl Bertil; Siegbahn Agneta; Simoons Maarten L; Topol Eric J; Venge Per; Wallentin Lars;
Troponin and C-reactive protein have different relations to subsequent mortality and myocardial infarction after acute coronary syndrome: a GUSTO-IV substudy.
Journal of the American College of Cardiology 2003;41(6):916-24.
2003: Holmvang Lene; Clemmensen Peter; Lindahl Bertil; Lagerqvist Bo; Venge Per; Wagner Galen; Wallentin Lars; Grande Peer
Quantitative analysis of the admission electrocardiogram identifies patients with unstable coronary artery disease who benefit the most from early invasive treatment.
Journal of the American College of Cardiology 2003;41(6):905-15.
2003: Johanson Per; Jernberg Tomas; Gunnarsson Gunnar; Lindahl Bertil; Wallentin Lars; Dellborg Mikael
Prognostic value of ST-segment resolution-when and what to measure.
European heart journal 2003;24(4):337-45.
2003: Oldgren J; Wallentin L; Grip L; Linder R; Nørgaard B L; Siegbahn A
Myocardial damage, inflammation and thrombin inhibition in unstable coronary artery disease.
European heart journal 2003;24(1):86-93.
2003: Ottervanger J P; Armstrong P; Barnathan E S; Boersma E; Cooper J S; Ohman E M; James S; Topol E; Wallentin L; Simoons M L;
Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial.
Circulation 2003;107(3):437-42.
2002: Bertrand Michel E; Simoons Maarten L; Fox Keith A A; Wallentin Lars C; Hamm Christian W; McFadden Eugene; De Feyter Pim J; Specchia Giuseppe; Ruzyllo Witold;
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.
European heart journal 2002;23(23):1809-40.
2002: Lagerqvist Bo; Husted Steen; Kontny Fredrik; Näslund Ulf; Ståhle Elisabeth; Swahn Eva; Wallentin Lars;
A long-term perspective on the protective effects of an early invasive strategy in unstable coronary artery disease: two-year follow-up of the FRISC-II invasive study.
Journal of the American College of Cardiology 2002;40(11):1902-14.
2002: Kereiakes Dean J; Montalescot Gilles; Antman Elliott M; Cohen Marc; Darius Harald; Ferguson James J; Grines Cindy; Karsch Karl R; Kleiman Neal S; Moliterno David J; Steg Phillippe-Gabriel; Teirstein Paul; Van de Werf Frans; Wallentin Lars
Low-molecular-weight heparin therapy for non-ST-elevation acute coronary syndromes and during percutaneous coronary intervention: an expert consensus.
American heart journal 2002;144(4):615-24.
2002: James S; Armstrong P; Califf R; Husted S; Kontny F; Niemminen M; Pfisterer M; Simoons M L; Wallentin L
Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes.
European heart journal 2002;23(19):1538-45.
2002: Wallentin Lars
Non-ST-elevation acute coronary syndrome: fuel for the invasive strategy.
Lancet 2002;360(9335):738-9.
2002: Husted S E; Wallentin L; Lagerqvist B; Kontny F; Ståhle E; Swahn E
Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization.
European heart journal 2002;23(15):1213-8.
2002: Jernberg Tomas; Cronblad Jörgen; Lindahl Bertil; Wallentin Lars
Observer variability and optimal criteria of transient ischemia during ST monitoring with continuous 12-lead ECG.
Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc 2002;7(3):181-90.
2002: Jernberg T; Abrahamsson P; Lindahl B; Johanson P; Wallentin L; Dellborg M
Continuous multilead ST-monitoring identifies patients with unstable coronary artery disease who benefit from extended antithrombotic treatment.
European heart journal 2002;23(14):1093-101.
2002: Aviles Ronnier J; Askari Arman T; Lindahl Bertil; Wallentin Lars; Jia Gang; Ohman E Magnus; Mahaffey Kenneth W; Newby L Kristin; Califf Robert M; Simoons Maarten L; Topol Eric J; Berger Peter; Lauer Michael S
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction.
The New England journal of medicine 2002;346(26):2047-52.
2002: Jacobsson Filip; Swahn Eva; Wallentin Lars; Ellborg Mikael
Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction.
Clinical therapeutics 2002;24(5):752-65.
2002: Stenestrand Ulf; Wallentin Lars
Early revascularisation and 1-year survival in 14-day survivors of acute myocardial infarction: a prospective cohort study.
Lancet 2002;359(9320):1805-11.
2002: Diderholm Erik; Andrén Bertil; Frostfeldt Gunnar; Genberg Margareta; Jernberg Tomas; Lagerqvist Bo; Lindahl Bertil; Venge Per; Wallentin Lars;
The prognostic and therapeutic implications of increased troponin T levels and ST depression in unstable coronary artery disease: the FRISC II invasive troponin T electrocardiogram substudy.
American heart journal 2002;143(5):760-7.
2002: Venge Per; Lagerqvist B o; Diderholm Erik; Lindahl Bertil; Wallentin Lars
Clinical performance of three cardiac troponin assays in patients with unstable coronary artery disease (a FRISC II substudy).
The American journal of cardiology 2002;89(9):1035-41.
2002: Frostfeldt Gunnar; Gustavsson Gunnar; Lindahl Bertil; Nygren Anders; Siegbahn Agneta; Wallentin Lars
Influence on coagulation activity by subcutaneous LMW heparin as an adjuvant treatment to fibrinolysis in acute myocardial infarction.
Thrombosis research 2002;105(3):193-9.
2002: Bahit Maria Cecilia; Granger Christopher B; Wallentin Lars
Persistence of the prothrombotic state after acute coronary syndromes: implications for treatment.
American heart journal 2002;143(2):205-16.
2002: Boersma Eric; Harrington Robert A; Moliterno David J; White Harvey; Théroux Pierre; Van de Werf Frans; de Torbal Anneke; Armstrong Paul W; Wallentin Lars C; Wilcox Robert G; Simes John; Califf Robert M; Topol Eric J; Simoons Maarten L
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.
Lancet 2002;359(9302):189-98.
2002: Diderholm E; Andrén B; Frostfeldt G; Genberg M; Jernberg T; Lagerqvist B; Lindahl B; Wallentin L
ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease; the FRISC II ECG substudy. The Fast Revascularisation during InStability in Coronary artery disease.
European heart journal 2002;23(1):41-9.
2001: Lindmark E; Diderholm E; Wallentin L; Siegbahn A
Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy.
JAMA : the journal of the American Medical Association 2001;286(17):2107-13.
2001: Lindahl B; Diderholm E; Lagerqvist B; Venge P; Wallentin L;
Mechanisms behind the prognostic value of troponin T in unstable coronary artery disease: a FRISC II substudy.
Journal of the American College of Cardiology 2001;38(4):979-86.
2001: Lindmark E; Wallentin L; Siegbahn A
Blood cell activation, coagulation, and inflammation in men and women with coronary artery disease.
Thrombosis research 2001;103(3):249-59.
2001: Lagerqvist B; Säfström K; Ståhle E; Wallentin L; Swahn E;
Is early invasive treatment of unstable coronary artery disease equally effective for both women and men? FRISC II Study Group Investigators.
Journal of the American College of Cardiology 2001;38(1):41-8.
2001: Oldgren J; Linder R; Grip L; Siegbahn A; Wallentin L
Coagulation activity and clinical outcome in unstable coronary artery disease.
Arteriosclerosis, thrombosis, and vascular biology 2001;21(6):1059-64.
2001: Frostfeldt G; Gustafsson G; Lindahl B; Nygren A; Venge P; Wallentin L
Possible reasons for the prognostic value of troponin-T on admission in patients with ST-elevation myocardial infarction.
Coronary artery disease 2001;12(3):227-37.
2001: Jernberg T; Abrahamsson P; Lindahl B; Wallentin L; Dellborg M
Comparison of continuous vectorcardiography and continuous 12-lead electrocardiography of patients with unstable coronary artery disease: do they identify the same population?
Coronary artery disease 2001;12(3):187-95.
2001: Venge P; Lindahl B; Wallentin L
New generation cardiac troponin I assay for the access immunoassay system.
Clinical chemistry 2001;47(5):959-61.
2001: Abrahamsson P; Andersen K; Grip L; Wallentin L; Dellborg M
Early assessment of long-term risk with continuous ST-segment monitoring among patients with unstable coronary syndromes. Results from 1-year follow-up in the TRIM study.
Journal of electrocardiology 2001;34(2):103-8.
2001: Wallentin L; Dellborg D M; Lindahl B; Nilsson T; Pehrsson K; Swahn E
The low-molecular-weight heparin dalteparin as adjuvant therapy in acute myocardial infarction: the ASSENT PLUS study.
Clinical cardiology 2001;24(3 Suppl):I12-4.
2001: Stenestrand U; Wallentin L;
Early statin treatment following acute myocardial infarction and 1-year survival.
JAMA : the journal of the American Medical Association 2001;285(4):430-6.
2000: Lindahl B; Toss H; Siegbahn A; Venge P; Wallentin L
Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.
The New England journal of medicine 2000;343(16):1139-47.
2000: Jernberg T; Lindahl B; Wallentin L
The combination of a continuous 12-lead ECG and troponin T; a valuable tool for risk stratification during the first 6 hours in patients with chest pain and a non-diagnostic ECG.
European heart journal 2000;21(17):1464-72.
2000: Wallentin L; Lagerqvist B; Husted S; Kontny F; Ståhle E; Swahn E
Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. FRISC II Investigators. Fast Revascularisation during Instability in Coronary artery disease.
Lancet 2000;356(9223):9-16.
2000: Wallentin L
Efficacy of low-molecular-weight heparin in acute coronary syndromes.
American heart journal 2000;139(2 Pt 2):S29-32.
2000: Wallentin L
Long-term management--the way forward?
Clinical cardiology 2000;23 Suppl 1():I13-7.
2000: Wallentin L
Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery disease -- an update of the Fragmin during Instability in Coronary Artery Disease II Trial.
Haemostasis 2000;30 Suppl 2():108-13; discussion 106-7.
2000: Wallentin L
Implications of the FRISCII trial: initial medical stabilization followed by an early invasive approach is the preferred strategy in unstable coronary syndromes.
Scandinavian cardiovascular journal : SCJ 2000;34(1):4-6.
1999: Wallentin L
Low-molecular-weight heparins in coronary thrombosis: today and tomorrow.
Haemostasis 1999;29 Suppl S1():32-7.
1999: Jernberg T; Lindahl B; Wallentin L
ST-segment monitoring with continuous 12-lead ECG improves early risk stratification in patients with chest pain and ECG nondiagnostic of acute myocardial infarction.
Journal of the American College of Cardiology 1999;34(5):1413-9.
1999: Oldgren J; Linder R; Grip L; Siegbahn A; Wallentin L
Activated partial thromboplastin time and clinical outcome after thrombin inhibition in unstable coronary artery disease.
European heart journal 1999;20(22):1657-66.
1999: Linder R; Oldgren J; Egberg N; Grip L; Larson G; Siegbahn A; Wallentin L
The effect of a low molecular mass thrombin inhibitor, inogatran, and heparin on thrombin generation and fibrin turnover in patients with unstable coronary artery disease.
European heart journal 1999;20(7):506-18.
1999: Frostfeldt G; Ahlberg G; Gustafsson G; Helmius G; Lindahl B; Nygren A; Siegbahn A; Swahn E; Venge P; Wallentin L
Low molecular weight heparin (dalteparin) as adjuvant treatment of thrombolysis in acute myocardial infarction--a pilot study: biochemical markers in acute coronary syndromes (BIOMACS II).
Journal of the American College of Cardiology 1999;33(3):627-33.
1999: Wallentin L
New antithrombotic treatment in unstable coronary syndrome--for whom?
Lancet 1999;353(9151):423-4.
1999: Toss H; Wallentin L; Siegbahn A
Influences of sex and smoking habits on anticoagulant activity in low-molecular-weight heparin treatment of unstable coronary artery disease.
American heart journal 1999;137(1):72-8.
1998: Lindahl B; Venge P; Wallentin L
The FRISC experience with troponin T. Use as decision tool and comparison with other prognostic markers.
European heart journal 1998;19 Suppl N():N51-8.
1998: Toss H; Gnarpe J; Gnarpe H; Siegbahn A; Lindahl B; Wallentin L
Increased fibrinogen levels are associated with persistent Chlamydia pneumoniae infection in unstable coronary artery disease.
European heart journal 1998;19(4):570-7.
1998: Ernofsson M; Strekerud F; Toss H; Abildgaard U; Wallentin L; Siegbahn A
Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease.
Thrombosis and haemostasis 1998;79(3):491-4.
1997: Toss H; Lindahl B; Siegbahn A; Wallentin L
Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease.
Circulation 1997;96(12):4204-10.
1997: Ellenius J; Groth T; Lindahl B; Wallentin L
Early assessment of patients with suspected acute myocardial infarction by biochemical monitoring and neural network analysis.
Clinical chemistry 1997;43(10):1919-25.
1997: Wallentin L; Husted S; Kontny F; Swahn E
Long-term low-molecular-weight heparin (Fragmin) and/or early revascularization during instability in coronary artery disease (the FRISC II Study).
The American journal of cardiology 1997;80(5A):61E-63E.
1997: Lindahl B; Andrén B; Ohlsson J; Venge P; Wallentin L
Noninvasive risk stratification in unstable coronary artery disease: exercise test and biochemical markers. FRISC Study Group.
The American journal of cardiology 1997;80(5A):40E-44E.
1997: Swahn E; Wallentin L
Low-molecular-weight heparin (Fragmin) during instability in coronary artery disease (FRISC). FRISC Study Group.
The American journal of cardiology 1997;80(5A):25E-29E.
1997: Lindahl B; Andrén B; Ohlsson J; Venge P; Wallentin L
Risk stratification in unstable coronary artery disease. Additive value of troponin T determinations and pre-discharge exercise tests. FRISK Study Group.
European heart journal 1997;18(5):762-70.
1997: Lindahl B; Venge P; Wallentin L
Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group.
Journal of the American College of Cardiology 1997;29(1):43-8.
1996: Wallentin L
Low molecular weight heparins: a valuable tool in the treatment of acute coronary syndromes.
European heart journal 1996;17(10):1470-6.
1996: Lindahl B; Venge P; Wallentin L
Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group.
Circulation 1996;93(9):1651-7.
1995: Larsson H; Areskog M; Areskog N H; Jonasson T; Ringqvist I; Fellenius C; Wallentin L
The diagnostic and prognostic importance of ambulatory ST recording compared to a predischarge exercise test after an episode of unstable angina or non-Q wave myocardial infarction.
European heart journal 1995;16(7):888-93.
1995: Karlsson J E; Björkholm A; Nylander E; Ohlsson J; Wallentin L
Additional value of thallium-201 SPECT to a conventional exercise test for the identification of severe coronary lesions after an episode of unstable coronary artery disease.
International journal of cardiac imaging 1995;11(2):127-37.
1995: Lindahl B; Venge P; Wallentin L
Early diagnosis and exclusion of acute myocardial infarction using biochemical monitoring. The BIOMACS Study Group. Biochemicals Markers of Acute Coronary Syndromes.
Coronary artery disease 1995;6(4):321-8.
1994: Blomstrand P; Karlsson J E; Engvall J; Nylander E; Björkholm A; Wallentin L; Wranne B
Exercise echocardiography and thallium 201 single-photon emission computed tomography in male patients after an episode of unstable coronary artery disease.
American journal of cardiac imaging 1994;8(4):283-9.
1994: Lindström T; Olsson A G; von Schenck H; Wallentin L; Arnqvist H J
Insulin treatment improves microalbuminuria and other cardiovascular risk factors in patients with type 2 diabetes mellitus.
Journal of internal medicine 1994;235(3):253-61.
1993: Karlsson J E; Björkholm A; Blomstrand P; Ohlsson J; Wallentin L
Ambulatory ST-recording has no additional value to exercise test for identification of severe coronary lesions after an episode of unstable coronary artery disease in men.
International journal of cardiac imaging 1993;9(4):281-9.
1993: Karlsson J E; Björkholm A; Nylander E; Ohlsson J; Swahn E; Wallentin L
ST-changes in ECG at rest or during exercise indicate a high risk of severe coronary lesions after an episode of unstable coronary artery disease.
International journal of cardiology 1993;42(1):47-55.
1993: Nyman I; Areskog M; Areskog N H; Swahn E; Wallentin L
Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease. The RISC Study Group.
Journal of internal medicine 1993;234(3):293-301.
1993: Nyman I; Wallentin L; Areskog M; Areskog N H; Swahn E
Risk stratification by early exercise testing after an episode of unstable coronary artery disease. The RISC Study Group.
International journal of cardiology 1993;39(2):131-42.
1992: Karlsson J E; Berglund U; Björkholm A; Ohlsson J; Swahn E; Wallentin L
Thrombolysis with recombinant human tissue-type plasminogen activator during instability in coronary artery disease: effect on myocardial ischemia and need for coronary revascularization. TRIC Study Group.
American heart journal 1992;124(6):1419-26.
1992: Blomstrand P; Engvall J; Karlsson J E; Björkholm A; Wallentin L; Wranne B
Exercise echocardiography: a methodological study comparing peak-exercise and post-exercise image information.
Clinical physiology (Oxford, England) 1992;12(5):553-65.
1992: Nyman I; Larsson H; Wallentin L
Prevention of serious cardiac events by low-dose aspirin in patients with silent myocardial ischaemia. The Research Group on Instability in Coronary Artery Disease in Southeast Sweden.
Lancet 1992;340(8818):497-501.
1992: Nyman I; Larsson H; Areskog M; Areskog N H; Wallentin L
The predictive value of silent ischemia at an exercise test before discharge after an episode of unstable coronary artery disease. RISC Study Group.
American heart journal 1992;123(2):324-31.
1992: Larsson H; Jonasson T; Ringqvist I; Fellenius C; Wallentin L
Diagnostic and prognostic importance of ST recording after an episode of unstable angina or non-Q-wave myocardial infarction.
European heart journal 1992;13(2):207-12.
1991: Wallentin L C
Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden.
Journal of the American College of Cardiology 1991;18(7):1587-93.
1991: Berglund U; Wallentin L
Influence on platelet function by heparin in men with unstable coronary artery disease.
Thrombosis and haemostasis 1991;66(6):648-51.
1991: Berglund U; Wallentin L
Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid daily in men with unstable coronary artery disease.
European heart journal 1991;12(3):428-33.
1991: Larsson H; Areskog M; Areskog N H; Nylander E; Nyman I; Swahn E; Wallentin L
Should the exercise test (ET) be performed at discharge or one month later after an episode of unstable angina or non-Q-wave myocardial infarction?
International journal of cardiac imaging 1991;7(1):7-14.
1989: Swahn E; von Schenck H; Wallentin L
Plasma fibrinogen in unstable coronary artery disease.
Scandinavian journal of clinical and laboratory investigation 1989;49(1):49-54.
1988: Berglund U; Wallentin L; von Schenck H
Platelet function and plasma fibrinogen and their relations to gender, smoking habits, obesity and beta-blocker treatment in young survivors of myocardial infarction.
Thrombosis and haemostasis 1988;60(1):21-4.
1987: Swahn E; Areskog M; Wallentin L
Prognostic importance of early exercise testing in men with suspected unstable coronary artery disease.
European heart journal 1987;8(8):861-9.
1987: Swahn E; Wallentin L
Platelet reactivity in unstable coronary artery disease.
Thrombosis and haemostasis 1987;57(3):302-5.
1987: Swahn E; Areskog M; Berglund U; Walfridsson H; Wallentin L
Predictive importance of clinical findings and a predischarge exercise test in patients with suspected unstable coronary artery disease.
The American journal of cardiology 1987;59(4):208-14.
1986: Swahn E; Areskog M; Wallentin L
Early exercise testing after coronary care for suspected unstable coronary artery disease--safety and diagnostic value.
European heart journal 1986;7(7):594-601.
1985: Berglund U; von Schenck H; Wallentin L
Effects of ticlopidine of platelet function in men with stable angina pectoris.
Thrombosis and haemostasis 1985;54(4):808-12.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Lars Wallentin

Research Profile (preview)

Disorders

Devices

Chemicals & Drugs

Concepts & Ideas

Procedures

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Lars Wallentin (preview)

All Publications